Literature DB >> 10379889

Titration by estrogen receptor activation function-2 of targets that are downstream from coactivators.

G N Lopez1, P Webb, J H Shinsako, J D Baxter, G L Greene, P J Kushner.   

Abstract

Cross-interference (squelching) among nuclear receptors has been proposed to reflect the titration of coactivators that bind the receptors in a hormone-dependent manner. We have tested whether the coactivators are the only target titrated during squelching of one receptor by another, or whether proteins needed for coactivator function are titrated as well. That the coactivators are indeed one target of squelching is apparent. The isolated ligand-binding domain of the estrogen receptor (ER-LBD) squelches transcriptional activation by the thyroid hormone receptor (TR) only when the LBD is bound to ligands that promote coactivator interactions and only when regions of the LBD that promote coactivator interactions are undisturbed. Furthermore, the ER-LBD and the TR compete in vitro for the related p160 coactivators, SRC1a and GRIP1 (glucocorticoid receptor interacting protein 1), or the putative corepressor, RIP140. Finally TR action becomes more potent when coactivator levels are raised. Nonetheless, supplying excess SRC1a or GRIP1 does not abolish squelching by the ER. In fact, squelching becomes even more severe when coactivators are abundant. Supplying combinations of coactivators from the p160 class and the CREB-binding protein (CBP)/p300 class makes squelching most severe. Elevated RIP140 inhibits TR action, but also protects the residual TR action from squelching by the ER-LBD. We conclude that ER-LBD squelches TR both by titrating p160-CBP coactivators and additionally by cooperating with the coactivators to titrate a second factor. The second factor would be needed by the TR for coactivator-mediated transcriptional stimulation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10379889     DOI: 10.1210/mend.13.6.0283

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  11 in total

1.  A dominant negative PPARgamma mutant shows altered cofactor recruitment and inhibits adipogenesis in 3T3-L1 cells.

Authors:  Y Park; B D Freedman; E J Lee; S Park; J L Jameson
Journal:  Diabetologia       Date:  2003-03-07       Impact factor: 10.122

2.  Functional analysis of the transcription factor ER71 and its activation of the matrix metalloproteinase-1 promoter.

Authors:  Luciano De Haro; Ralf Janknecht
Journal:  Nucleic Acids Res       Date:  2002-07-01       Impact factor: 16.971

3.  Targeted skin overexpression of the mineralocorticoid receptor in mice causes epidermal atrophy, premature skin barrier formation, eye abnormalities, and alopecia.

Authors:  Yannis Sainte Marie; Antoine Toulon; Ralf Paus; Eve Maubec; Aicha Cherfa; Maggy Grossin; Vincent Descamps; Maud Clemessy; Jean-Marie Gasc; Michel Peuchmaur; Adam Glick; Nicolette Farman; Frederic Jaisser
Journal:  Am J Pathol       Date:  2007-08-03       Impact factor: 4.307

4.  Angiotensin II type 2 receptor stimulation with compound 21 improves neurological function after stroke in female rats: a pilot study.

Authors:  Wael Eldahshan; Tauheed Ishrat; Bindu Pillai; Mohammed A Sayed; Abdulrahman Alwhaibi; Abdelrahman Y Fouda; Adviye Ergul; Susan C Fagan
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-03-01       Impact factor: 4.733

5.  17β-Estradiol inhibition of PPARγ-induced adipogenesis and adipocyte-specific gene expression.

Authors:  Sunhyo Jeong; Michung Yoon
Journal:  Acta Pharmacol Sin       Date:  2011-02       Impact factor: 6.150

6.  PPARα in Obesity: Sex Difference and Estrogen Involvement.

Authors:  Michung Yoon
Journal:  PPAR Res       Date:  2010-08-17       Impact factor: 4.964

7.  Functional estrogen receptors in the mitochondria of breast cancer cells.

Authors:  Ali Pedram; Mahnaz Razandi; Douglas C Wallace; Ellis R Levin
Journal:  Mol Biol Cell       Date:  2006-02-22       Impact factor: 4.138

8.  Metabolic actions of estrogen receptor beta (ERbeta) are mediated by a negative cross-talk with PPARgamma.

Authors:  Anna Foryst-Ludwig; Markus Clemenz; Stephan Hohmann; Martin Hartge; Christiane Sprang; Nikolaj Frost; Maxim Krikov; Sanjay Bhanot; Rodrigo Barros; Andrea Morani; Jan-Ake Gustafsson; Thomas Unger; Ulrich Kintscher
Journal:  PLoS Genet       Date:  2008-06-27       Impact factor: 5.917

9.  Phenotypic alterations in breast cancer cells overexpressing the nuclear receptor co-activator AIB1.

Authors:  Sarah L Anzick; David O Azorsa; S Stoney Simons; Paul S Meltzer
Journal:  BMC Cancer       Date:  2003-09-10       Impact factor: 4.430

10.  A conserved lysine in the estrogen receptor DNA binding domain regulates ligand activation profiles at AP-1 sites, possibly by controlling interactions with a modulating repressor.

Authors:  Rosalie M Uht; Paul Webb; Phuong Nguyen; Richard H Price; Cathleen Valentine; Helene Favre; Peter J Kushner
Journal:  Nucl Recept       Date:  2004-05-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.